Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanisms of action in exposure therapy with D-cycloserine
2010-023044-32Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Mar 2011
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of d-cycloserine in panic disorder and agoraphobia, sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Changes in neuronal activation patterns in extinction circuit. Started Mar 2011; status: completed.
02
Drugs
d-cycloserine
03
Conditions
panic disorderagoraphobia
Beyond the preview
Go deeper on 2010-023044-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023044-32.